Literature DB >> 8025685

Genotype and phenotype of oral Candida albicans from patients infected with the human immunodeficiency virus.

M J McCullough1, B C Ross, B D Dwyer, P C Reade.   

Abstract

Candida albicans has been shown to vary in its phenotypic expression with the progression of human immunodeficiency virus (HIV) infection. Isolates of C. albicans were obtained from 45 patients with HIV infection during the progression of their disease and differentiated using two methods. The first utilized the morphological characteristics of colonies, and the second method utilized a small portion of C. albicans DNA as a probe on Southern-transferred, EcoRI-digested C. albicans genomic DNA. In 67% of the patients a single strain of C. albicans, as determined by the DNA analysis, was isolated from each individual. The phenotypic expression of the genetically identical strains varied considerably over the experimental period with one morphotype being predominant. These results showed that the genotype of C. albicans persisted in the majority of HIV-infected individuals, but that the phenotypical expression of this strain changed. A novel finding in this study was that 18 strains of C. albicans had DNA which did not hybridize to the probe used.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025685     DOI: 10.1099/13500872-140-5-1195

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  20 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis.

Authors:  J R Naglik; G Newport; T C White; L L Fernandes-Naglik; J S Greenspan; D Greenspan; S P Sweet; S J Challacombe; N Agabian
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting.

Authors:  P Boerlin; F Boerlin-Petzold; J Goudet; C Durussel; J L Pagani; J P Chave; J Bille
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 4.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

5.  Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates.

Authors:  P Steffan; J A Vazquez; D Boikov; C Xu; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

6.  Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus.

Authors:  M McCullough; B Ross; P Reade
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance profiles.

Authors:  A Lischewski; M Ruhnke; I Tennagen; G Schönian; J Morschhäuser; J Hacker
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

8.  Highly polymorphic microsatellite for identification of Candida albicans strains.

Authors:  Paula Sampaio; Leonor Gusmão; Cíntia Alves; Cidália Pina-Vaz; António Amorim; Célia Pais
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

9.  Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes.

Authors:  J Bikandi; R S Millán; M D Moragues; G Cebas; M Clarke; D C Coleman; D J Sullivan; G Quindós; J Pontón
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 10.  Candida albicans secreted aspartyl proteinases in virulence and pathogenesis.

Authors:  Julian R Naglik; Stephen J Challacombe; Bernhard Hube
Journal:  Microbiol Mol Biol Rev       Date:  2003-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.